Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice
Avtorji:ID Omerzel, Maša (Avtor)
ID Jesenko, Tanja (Avtor)
ID Markelc, Boštjan (Avtor)
ID Janžič, Larisa (Avtor)
ID Čemažar, Maja (Avtor)
ID Serša, Gregor (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (3,74 MB)
MD5: 1B2A7A6917FD419DB6A245FCA0640FF5
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Electrochemotherapy (ECT), a local therapy, has different effectiveness among tumor types. In breast can-cer, its effectiveness is low; therefore, combined therapies are needed. The aim of our study was to com-bine ECT with PARP inhibitor olaparib, which could inhibit the repair of bleomycin or cisplatin inducedDNA damage and potentiate the effectiveness of ECT. The effects of combined therapy were studied inBRCA1mutated (HCC1937) and non-mutated (HCC1143) triple negative breast cancer cell lines.Therapeutic effectiveness was studied in 2D and 3D cell cultures andin vivoon subcutaneousHCC1937 tumor model in mice. The underlying mechanism of combined therapy was determined withthe evaluation ofcH2AX foci. Combined therapy of ECT with bleomycin and olaparib potentiated theeffectiveness of ECT inBRCA1mutated HCC1937, but not in non-mutated HCC1143 cells. The combinedtherapy had a synergistic effect, which was due to the increased number of DNA double strand breaks.Addition of olaparib to ECT with bleomycinin vivoin HCC1937 tumor model had only minimal effect,indicating repetitive olaparib treatment would be needed. This study demonstrates that DNA repar inhibiting drugs, like olaparib, have the potential to increase the effectiveness of ECT with bleomycin.
Ključne besede:electrochemotherapy, breast cancer, olaparib, bleomycin
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.05.2021
Založnik:Elsevier
Leto izida:2021
Št. strani:str. 107832-1-10783-12
Številčenje:Vol. 140
PID:20.500.12556/DiRROS-15564 Novo okno
UDK:602.6/.7
ISSN pri članku:1567-5394
DOI:10.1016/j.bioelechem.2021.107832 Novo okno
COBISS.SI-ID:66822915 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:21.09.2022
Število ogledov:494
Število prenosov:169
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Bioelectrochemistry
Založnik:Elsevier
ISSN:1567-5394
COBISS.SI-ID:2502484 Novo okno

Gradivo je financirano iz projekta

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:Z3-1871-2019
Naslov:Kombinacija elektrokemoterapije in zaviralca poli (adenozin difosfat-riboza) polimeraze pri zdravljenju raka dojke

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0003-2015
Naslov:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Začetek licenciranja:21.09.2022

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:elektrokemoterapija, rak dojke, olaparib, bleomycin


Nazaj